Matthew J.; and Diamond, Michael S., ,"A library of infectious hepatitis C viruses with engineered mutations in the E2 gene reveals growth-adaptive mutations that modulate interactions with scavenger receptor class B type I." The Journal of Virology.,. 1-47. (2016 HCV with all codons represented at most positions in the ectodomain of the E2 gene. We 29 identified many putative growth adaptive mutations and selected nine highly represented E2 30 mutants for further study: Q412R, T416R, S449P, T563V, A579R, L619T, V626S, K632T, and 31 L644I. We evaluated these mutants for changes in particle to infectious unit ratio, sensitivity to 32 neutralizing antibody or CD81 large extracellular loop (CD81-LEL) inhibition, entry factor usage, 33 and buoyant density profiles. Q412R, T416R, S449P, T563V and L619T were neutralized more 34 efficiently by anti-E2 antibodies and T416R, T563V and L619T by CD81-LEL. Remarkably, all 35 nine variants showed reduced dependence on scavenger receptor class B type I (SR-BI) for 36 infection. This shift from SR-BI usage did not correlate with a change in the buoyant density 37 profiles of the variants, suggesting an altered E2-SR-BI interaction rather than changes in the 38 virus-associated lipoprotein-E2 interaction. Our results demonstrate that residues influencing 39 SR-BI usage are distributed across E2 and support the development of large scale mutagenesis 40 studies to identify viral variants with unique functional properties. 
INTRODUCTION 55
Hepatitis C virus (HCV) infection causes a major global health burden, as 56 approximately 3% of the world's population is affected (1). Up to 30% of individuals with HCV 57 will resolve infection spontaneously, whereas the majority develop chronic infections that can 58 cause fibrosis, cirrhosis, and hepatocellular carcinoma (2). HCV is a member of the hepacivirus 59 cells by the mutants. We therefore performed a second growth kinetic analysis using the TCID 50 177 method of virus titration to quantify virus. Huh7.5 cells were infected at an MOI of 0.05 with each 178 of the clonal growth-adapted mutants as described above, and viral yield in supernatant was 179 collected 5 days post-infection and calculated. 180 HCV genome quantification. qRT-PCR was used to quantify genome copy number in 181 virus-containing supernatants. Viral RNA was harvested using QIAamp® Viral RNA Mini Kit 182 (Qiagen). All reactions were prepared using a TaqMan® RNA-to-C T gene editing, we generated expression plasmids encoding the U6 promoter in front of SR-BI 218 specific guide RNAs (35). Two rounds of overlapping PCR were performed by amplifying a 219 guide RNA encoding plasmid (provided by George Church, Harvard University, Boston, MA, 220
Addgene plasmid # 41819): in the first round, PCR products were generated encompassing the 221 U6 promoter through the 5′ end of the guide RNA (consisting of the specific target sequence) 222 with the ME-O-1122 oligonucleotide (5′-CGGGCCCCCCCTCGAGTGTACAAAAAAGCAGGCT-223 3′) and an SR-BI target sequence specific reverse oligonucleotide (see list below). A second 224 PCR product was generated encompassing a region from the SR-BI target sequence through 225 the end of the guide RNA coding sequence with a forward direction CLDN1 target sequence 226 specific oligonucleotide (ME-O-1138; 5′-GCTTCATTCTCGCCTTCCGTTTTAGAGCTAGAAATA-227 3′). These products were re-amplified with only the outside oligonucleotides, ME-O-1122 and - Harvard University, Boston, MA, Addgene plasmid # 41815) (35) and a pooled mixture of the 244 above SR-BI guide RNA expression plasmids. Transfected cells were passaged for one to two 245 weeks to allow the turnover of previously translated target protein. Cells were then subjected to 246 fluorescence activated cell sorting (FACS) for loss of SR-BI following staining with the anti-SR-247 B1 antibody (mAb16-71) and a goat anti-human Alexa-647 antibody (Invitrogen, Carlsbad, CA). 248
Knockout of SR-BI efficiency prior to sorting was 11-15%. Single cell clones were obtained by 249 limiting dilution cloning in 96-well plates. Individual clones were expanded and assayed for SR-250 BI expression by flow cytometry with the mAb16-71 antibody, and the capacity to support HCV 251 infection, as previously described (9). We chose Huh7.5 SR-BI KO inactivating lentiviral provirus TRIP-GFP-linker was used (31). For SR-BI expression, the TRIP-256 GFP-hu-SR-BI-linker provirus was used. VSV-G pseudotyped lentiviral stocks were produced in 257 293T cells, as previously described (31, 36). Supernatants were collected 2 days post 258 transfection and used to infect gene-edited Huh7.5 cells, also as previously described (31, 36). 259
Cells were expanded for at least two weeks prior to analysis. (Fig 1A) . Three hundred and twenty primer sets containing three random 291 nucleotides (NNN) corresponding to one codon in the ectodomain of E2 were designed. Using 292 these primers and a JFH-1 infectious clone plasmid, we performed separate SDSM reactions 293 with each primer pair yielding 320 plasmid libraries. To simplify production of infectious virus, we 294 grouped the plasmid libraries into 32 sets of 10 adjacent codons for all downstream steps. To 295
confirm that each plasmid library contained 64 engineered variants (all nucleotide combinations 296 at each codon) we performed amplicon sequencing of the 32 sets of 10 pooled single codon 297 plasmid libraries (Fig 1B) . Under ideal conditions we expected a 10% mutation rate for a single 298 codon within the ten plasmid pool containing variability at that position; our library had an 299 average mutation rate of 6.0%. To produce infectious HCV, we transcribed RNA genomes in 300 vitro from the pooled plasmids and electroporated each of 32 RNA stocks into Huh7.5 cells. By 301 the end of this process, we had created 32 viral "pools" with each containing maximum 302 variability at ten positions in E2. that were enriched by passaging, we generated cDNA from P3 viruses, and TOPO-cloned the 310 E1-E2 genome fragment amplicons produced by PCR. We sequenced the E2 gene for 24 to 48 311 resultant bacterial colonies from each of the 8 P3 viruses with consensus sequence changes 312 ( Table 1) . 313
Based on these results, nine variants that corresponded to the dominant amino acid 314 substitution in each of the P3 viruses were selected for further study: Q412R, T416R, S449P, 315 T563V, A579R, L619T, V626S, K632T, and L644I. Four of these residues (Q412, T416, S449 316 and T563) are at or very near to positions in E2 that have been reported as adaptive mutations 317 (38-41, 45), with the remainder not having been described to affect growth. Sequencing of 318 individual clones suggested that multiple substitutions at a given position might confer growth 319 advantage over the parent virus with the exception of S449, which had only proline 320 substitutions. S449P also was unique, as it eliminated a predicted N-linked glycosylation site at 321
N448. 322
Clonal mutant viruses show enhanced growth kinetics. We used conventional site 323 directed mutagenesis to introduce the nine dominant mutations into the parental infectious 324 clone. Following verification by complete genome sequencing of the plasmids, mutant viruses 325 were generated after electroporation of in vitro derived RNA into Huh7.5 cells and titered using 326 the TCID 50 method. To validate the significance of the mutations, multi-step viral growth 327 analyses were performed by FFA after infection of Huh7.5 cells (MOI of 0.1) with each mutant 328 and the parental virus (Fig 2A) . Whereas each of the mutations conferred a growth advantage 329 compared to the parental virus, we noticed that the input virus titer (t = 0) for all of the mutant 330 viruses appeared higher than the parent JFH-1 in this assay. Because we inoculated with 331 equivalent input amounts based on the TCID 50 assay, we hypothesized that the difference at t = 332 0 of the input virus reflected the more rapid growth of the adaptive mutant strains over the 333 were collected five days later and titered by TCID 50 assay (Fig 2B) . Using this second method, 337 the mutants exhibited a 5-and 10-fold growth advantage compared to the parental viruses. In 338 this assay, the V626S mutant did not show a statistically significant growth advantage compared 339 to the parental strains. Nonetheless, it may still be a growth adaptive mutation based on 340 accumulated data ( Table 1, Fig 2) . 341
Particle to infectious unit ratios for E2 mutants. We next explored whether there 342 were functional differences in the properties of growth-adapted viruses compared to the parent 343 JFH-1 strain. We initially assessed the relative specific infectivity by measuring the RNA:TCID 50 344 ratio of each mutant virus ( Table 2) . A more efficient assembly process or increased stability of 345 infectious virions could contribute to increased peak titers. As HCV growth kinetic assays are 346 long, small differences may compound over time and account for at least part of the adaptive 347 growth phenotype. Using the tittered samples described in Fig 2B, viral RNA was harvested and 348 genome copy determined via RT-PCR using in vitro derived-RNA from infectious clone plasmids 349 as standards. The greatest difference between parent and a mutant virus was observed for 350 T563V, and even this fold-change was less than 4-fold. All mutant viruses, apart from K632T, 351 had a lower RNA:TCID 50 ratio than the parental virus, although these differences did not 352 achieve statistical significance. quantified the density, viral titer, and HCV genome copy number in each fraction collected (Fig  362   3) . The mutants all behaved similarly to parent virus, suggesting they have similar lipoprotein 363 utilization or incorporation. 364
Some adaptive mutations enhance CD81-LEL and NMAb sensitivity. E2 is the major 365 viral target of neutralizing antibodies during infection. Many of the most effective broadly NMAbs 366 block interaction between E2 and CD81, one of the key HCV entry receptors (30, 31, 51, 52). 367
Some growth-adaptive mutations in E2 were shown to increase inhibition by soluble CD81-LEL 368
and NMAbs (37, 39, 40). To assess whether the identified mutations affected the binding of E2 369
to CD81, we performed inhibition of infection assays with a soluble CD81-LEL (Fig 4A) . A 370 subset of adaptive mutant viruses (T416R, T563V, and L619T) were inhibited more efficiently by 371 CD81-LEL than the parent JFH-1 virus (>5-fold decrease in EC 50 , P < 0.05), and thus an 372 enhanced CD81-E2 interaction might contribute to the growth advantages of these viruses. 373
However, most of the mutants were not more sensitive to CD81-LEL inhibition, which contrasts 374 with some published growth-adaptive variants. 375
We next performed dose-response inhibition of infection assays with two broadly 376 neutralizing anti-E2 NMAbs, H77.39 (Fig 4B) and HC84.26 (Fig 4C) , both of which block 377 interactions between E2 and CD81 (30, 31). H77.39 maps to an epitope centered on amino 378 acids 415 and 417 and part of a larger epitope between positions 412-421. Residues within this 379 region, especially W420, can influence CD81 interactions (24, 39). HC84.26 maps to conserved 380 residues within the CD81 biding site between residues 441 and 446 and to residue 620 (H77 381 residue numbers). Q412R, T416R, S449P, T563V, and L619T viruses were neutralized more 382 efficiently by H77.39 than the parent JFH1 (>5-fold decrease in EC 50 , P < 0.0001) (Fig 4B) and 383 T416R, S449P and T563V viruses were inhibited to a greater extent (>5-fold decrease in EC 50 , 384 P < 0.05) by HC84.26 (Fig 4C) . However, A579R, V626S, K632T and L644I viruses were 385 unchanged or exhibited modestly shifted profiles with anti-E2 NMAbs and CD81-LEL. 
adaptive mutant viruses were inhibited by anti-CD81 and anti-CLDN1 similarly compared to the 394 parental strain, suggesting little change in dependency on these receptors (Fig 5) . 395
Growth-adaptive mutants are less-dependent on SR-BI for infection.
Markedly 396 different neutralization profiles were observed for the mutants when an anti-SR-BI antibody was 397 used (Fig 6) , as each variant was more resistant to antibody inhibition. Whereas the parental 398 JFH-1 had a lower asymptote of 14% relative infection (i.e. resistant fraction), some mutant 399 viruses appeared to be entirely resistant to anti-SR-BI treatment of Huh7.5 cells. Even the most 400 sensitive mutant virus had a lower asymptote at 34% relative infection, 2.5-fold greater than 401 parent. To confirm changes to SR-BI dependency, we generated SR-BI KO Huh7.5 cells using 402 CRISPR/Cas9 gene editing (Fig 7) . A clonal SR-BI KO Huh7.5 line, clone 16, was selected for 403 further study. Clone 16 was confirmed to lack SR-BI expression (Fig 7A) and exhibited a 404 moderately impaired capacity to support HCV cell entry (Fig 7B) . Importantly, this phenotype 405 was restored completely by trans-complementation from a lentiviral vector (Fig 7B) . Paired 406 infections of control (GFP) and SR-BI (SR-BI + GFP) trans-complemented SR-BI KO 
cells with 407
WT and mutant HCV corroborated the anti-SR-BI antibody data: the mutants showed greater 408 infection in cells lacking SR-BI compared to the parental virus (Fig 7C) . Thus, growth adaptation 409 (Fig 7D) . Finally, we explored whether deletion of SR-BI from Huh7.5 cells differentially affected 416 the attachment of parent and mutant viruses. Notably, the attachment of all viruses to the SR-BI 417 gene-edited cells was similar, suggesting the mutations likely affect a post-attachment 418 interaction step that requires SR-BI (Fig 7E) . 419
Our results suggested that all of the growth adaptive mutations identified in our screen 420 modulated the SR-BI dependence of HCV for entry into target cells. When we mapped the 421 positions of the growth adaptive mutations on the E2 core structure (19), we found that four of 422 the residues (L619T, V626S and K632T, and L644I) were proximal to one another, with K632T, 423 and L644I directly adjacent in an anti-parallel beta hairpin (Fig 7F) . This clustering suggests a 424 possible role for this region of E2 in an interaction with SR-BI. (http://www.viprbrc.org/) revealed that our adaptive mutations were present at low frequencies 453 or absent from most HCV isolates (Table 3) . A subset of our mutations, Q412R, T416R, S449P, 454 T563V, and L619T, were more sensitive to NMAb inhibition than the parental virus. Of these, 455 T416R, T563V and L619T also were more sensitive to inhibition by CD81-LEL. T416R falls 456 within the epitope of H77.39 and correspondingly is neutralized more efficiently by this antibody. 457
The S449P mutation eliminates a predicted N-linked glycosylation site at N448 near the CD81 458 binding site, which might enhance NMAb potency by reducing steric hindrance of the glycan. At 459 present, the effects of other residues on the potency of neutralization by H77.39 and HC84.26 460 are more challenging to model. Structural data for the binding of these antibodies to E2 are not 461 available, and some of the residues are not visible in the crystal structures of the E2 core. While it is known that deletion of HVR1 abrogates binding of E2 to SR-BI, the details of 493 this interaction remain unclear. Our findings, along with data from previous studies, suggest that 494 reduced SR-BI dependence for infection is a common feature of growth-enhancing E2 495 mutations (at least in cell culture) and that residues distributed across the E2 protein can 496 modulate the interaction with SR-BI. As four of the sites of growth adaptive mutations we 497 identified with altered SR-BI dependency were proximal to each other, we speculate this could 498 represent part of a possible SR-BI binding site in E2. The molecular basis for why our mutants 499
show less dependency on SR-BI awaits more detailed structural or biochemical resolution of the 500
E2 and SR-BI interaction. 501
In summary, we developed a novel E2 JFH-1 mutant library with significant diversity and 502 differences that are statistically significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 733 0.0001; ns, not significant). The results are the average of three independent experiments 734 performed in duplicate. 735 
